Akero Therapeutics, Inc.
AKRO
Kedudukan dalam Saham
#3739
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Harga Saham
$54.65
Disegerakkan terakhir: 2025-12-09
Modal Pasaran
$4.50B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
1.37%
Negara
US
Perdagangan Akero Therapeutics, Inc. (AKRO)
Kategori
Healthcare
Bilangan saham terbitan bagi Akero Therapeutics, Inc. (AKRO)
Bilangan saham terbitan setakat September 2025: 82.01M
Menurut laporan kewangan terkini dan harga saham Akero Therapeutics, Inc., bilangan saham terbitan semasa ialah 82.01M. Pada akhir December 2023, syarikat mempunyai 52.57M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Akero Therapeutics, Inc. (AKRO) dari 2017 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 82.01M | 22.15% |
| 2024 | 67.14M | 27.71% |
| 2023 | 52.57M | 34.84% |
| 2022 | 38.98M | 11.94% |
| 2021 | 34.83M | 10.69% |
| 2020 | 31.46M | 108.77% |
| 2019 | 15.07M | -28.99% |
| 2018 | 21.22M | -25.67% |
| 2017 | 28.56M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 209.60% |
US
|
|
| 396.00M | 382.88% |
US
|
|
| 478.91M | 483.98% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -24.17% |
NL
|
